HemoCue Hb 801 System

K181751 · Hemocue AB · GKR · Feb 1, 2019 · Hematology

Device Facts

• Record ID: K181751
• Device Name: HemoCue Hb 801 System
• Applicant: Hemocue AB
• Product Code: GKR · Hematology
• Decision Date: Feb 1, 2019
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 864.5620
• Device Class: Class 2
• Attributes: Pediatric

Indications for Use

The HemoCue® Hb 801 System is intended for the quantitative determination of hemoglobin in capillary or venous whole blood (K2EDTA and Li-Heparin) in point-of-care settings. The HemoCue® Hb 801 System is intended to be used to determine the hemoglobin concentration for adults, adolescents, children, and infants above 1 month old. The HemoCue® Hb 801 System is for professional in vitro diagnostic use only.

Device Story

System consists of analyzer and single-use microcuvettes; performs quantitative hemoglobin determination in capillary or venous whole blood. User draws ~10 µL blood into microcuvette via capillary action; no dilution/preparation required. Microcuvette inserted into analyzer; device measures absorbance of whole blood at Hb/HbO2 isosbestic point using transmitted and scattered light. Algorithm translates optical measurements into hemoglobin concentration. Used in point-of-care settings by professional staff. Provides digital display of results; supports USB/Bluetooth connectivity. Internal self-test verifies optronic performance. Enables rapid clinical assessment of hemoglobin levels; aids in diagnosis/monitoring of anemia or other conditions requiring hemoglobin measurement.

Clinical Evidence

Bench testing only. Method comparison study (n=497 samples) vs. predicate showed high correlation (r=0.99 combined). Precision studies (n=75-420 replicates) demonstrated acceptable reproducibility across multiple sites, operators, and microcuvette lots. Linearity confirmed across 1.0–25.6 g/dL range. Interference testing evaluated various disease states and substances; specific interferents (bilirubin, Intralipid, high leukocytes) identified at high concentrations. Accuracy validated against HiCN reference method.

Technological Characteristics

Spectrophotometric analyzer; single-use microcuvette (pipette/measuring chamber). Factory calibrated; no user calibration required. Connectivity: Bluetooth Low Energy (BLE), USB. Power: adapter or batteries. Software: moderate level of concern. Standards: CLSI EP05-A3, EP06-A, EP07-A2, EP09-A3, EP17-A2, EP25-A, EP28-A3c, H15-A3; IEC 61010-1, 61010-2-101, 61326-1, 61326-2-6, 62304; ISO 14971; FCC Part 15.

Indications for Use

Indicated for quantitative hemoglobin determination in capillary or venous whole blood (K2EDTA/Li-Heparin) in point-of-care settings for adults, adolescents, children, and infants >1 month old. For professional IVD use only.

Regulatory Classification

Identification

An automated hemoglobin system is a fully automated or semi-automated device which may or may not be part of a larger system. The generic type of device consists of the reagents, calibrators, controls, and instrumentation used to determine the hemoglobin content of human blood.

Predicate Devices

• HemoCue® Hb 301 System (K061047)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION MEMORANDUM

A. 510(k) Number:
K181751

B. Purpose for Submission:
Clearance of a new device

C. Measurand:
Hemoglobin

D. Type of Test:
Quantitative determination of hemoglobin

E. Applicant:
HemoCue AB

F. Proprietary and Established Names:
HemoCue Hb 801 System

G. Regulatory Information:

1. Regulation section:
21 CFR 864.5620, Automated hemoglobin system

2. Classification:
Class II

3. Product code:
GKR, System, hemoglobin, automated

4. Panel:
Hematology (81)

{1}

H. Intended Use:

1. Intended use(s):

The HemoCue Hb 801 System is intended for the quantitative determination of hemoglobin in capillary or venous whole blood (K₂EDTA and Li-Heparin) in point-of-care settings. The HemoCue Hb 801 System is intended to be used to determine the hemoglobin concentration for adults, adolescents, children, and infants above 1 month old. The HemoCue Hb 801 System is for professional in vitro diagnostic use only.

2. Indication(s) for use:

Same as intended use

3. Special conditions for use statement(s):

For prescription use only

4. Special instrument requirements:

HemoCue Hb 801 Analyzer

I. Device Description:

The HemoCue Hb 801 System consists of the following parts: HemoCue Hb 801 Analyzer and HemoCue Hb 801 Microcuvettes. The HemoCue Hb 801 Microcuvettes are single-use cuvettes made of polystyrene plastic which do not contain reagents or active ingredients. The HemoCue Hb 801 Analyzer contains a microcuvette holder. The microcuvette serves both as a pipette and as a measuring cuvette. A whole blood sample of approximately 10 μL is drawn into the cavity of the microcuvette by capillary action. The HemoCue Hb 801 Analyzer provides a direct reading of the hemoglobin concentration on a display screen and has the ability to transmit results by wired connection with the USB cable connected to the power adapter or wirelessly by Bluetooth connection.

J. Substantial Equivalence Information:

1. Predicate device name(s):

HemoCue Hb 301 System

2. Predicate 510(k) number(s):

K061047

3. Comparison with predicate:

{2}

| Similarities | | |
| --- | --- | --- |
| Item | Candidate
HemoCue Hb 801 System | Predicate
HemoCue Hb 301 System
K061047 |
| Intended Use | The HemoCue Hb 801 System is intended for the quantitative determination of hemoglobin in capillary or venous whole blood (K±EDTA and Li-Heparin) in point-of-care settings. The HemoCue Hb 801 System is intended to be used to determine the hemoglobin concentration for adults, adolescents, children, and infants above 1 month old. The HemoCue Hb 801 System is for professional in vitro diagnostic use only. | The HemoCue Hb 301 System is designed for quantitative point-of-care whole blood hemoglobin determination in primary care using a specially designed analyzer, the HemoCue Hb 301 Analyzer, and specially designed microcuvettes, the HemoCue Hb 301 Microcuvettes. The HemoCue Hb 301 System is for In Vitro Diagnostic use only. The HemoCue Hb 301 Analyzer is only to be used with HemoCue Hb 301 Microcuvettes. |
| Analyte | Hemoglobin | Same |
| Sample preparation (pre-treatment) | None | Same |
| Sample volume | 10 μL | Same |
| Measurement principle | Spectrophotometric | Same |
| Reagent | No active ingredients in microcuvettes | Same |
| Result | Quantitative | Same |
| Calibration | The system is traceable to the hemiglobincyanide (HiCN) method, according to ICSH (International Council for Standardization in Haematology). The system is factory calibrated and needs no further calibration. | Same |
| Quality control | Internal self-test (verifying analyzer performance)
External quality control
HemoTrol WB | Same |
| Operating temperature | 10–40°C (50–104°F) | Same |
| Microcuvette Storage | 10–40°C (50–104°F) | Same |

{3}

| Differences | | |
| --- | --- | --- |
| Item | Device HemoCue Hb 801 System | Predicate HemoCue Hb 301 System K061047 |
| Sample type | Capillary or venous whole blood | Capillary, venous or arterial whole blood |
| Measuring range | 1–25.6g/dL | 0–25.6 g/dL |
| Connectivity | • Wireless Bluetooth Low • Energy (Bluetooth Low Energy) • USB | Serial port |
| Microcuvette insertion technique | Slot in | Place on a tray |
| Dimensions | 87×143×45 mm (3.4×5.6×1.8 inch) | 160×140×70 mm (6.3×5.5×2.8 inch) |
| Power sources | • USB adapter • 3 × AA battery • Rechargeable Li-Ion Battery | • AC adapter • 4 × AA battery |
| User interface | • Display • Beeper • Two buttons • Status LED | • Display • Beeper • One button |
| Result memory | Up to 4000 results | No |
| Clock (Date/time) | Yes | No |

# K. Standard/Guidance Document Referenced (if applicable):

CLSI EP05-A3; Evaluation of Precision Performance of Qualitative Measurement Methods; Approved Guideline - Third Edition.

CLSI EP06-A; Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline.

CLSI EP07-A2; Interference Testing in Clinical Chemistry; Approved Guideline - Second Edition.

CLSI EP07; Interference Testing in Clinical Chemistry; Approved Guideline -Third Edition

CLSI EP17-A2; Evaluation of Detection Capability for Clinical Laboratory Measurement Procedures; Approved Guideline - Second Edition.

CLSI EP25-A; Evaluation of Stability of In Vitro Diagnostic Reagents; Approved Guideline.

CLSI EP28-A3c; Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline - Third Edition.

CLSI EP37; Supplemental Tables for Interference Testing in Clinical Chemistry - First Edition

{4}

CLSI H15-A3; Reference and Selected Procedures for the Quantitative Determination of Hemoglobin in Blood; Approved Standard - Third Edition.

IEC 61010-1: 2010 (Third Edition) + AMD1:2016, Safety requirements for electrical equipment for measurement, control and laboratory use – Part 1: General requirements.

IEC 61010-2-101:2015 (Second Edition), Safety requirements for electrical equipment for measurement, control and laboratory use – Part 2-101: Particular requirements for in vitro diagnostic (IVD) medical equipment.

IEC 61326-1:2012 (Second Edition), Electrical equipment for measurement, control and laboratory use – EMC requirements – Part 1: General requirements.

IEC 61326-2- 6:2012, Electrical equipment for measurement, control and laboratory use - EMC requirements - Part 2-6: Particular requirements - In vitro diagnostic (IVD) medical equipment

IEC 62304:2006, Medical device software - Software life cycle processes

ISO 14971:2007, Medical devices - Application of risk management to medical devices

## L. Test Principle:

According to the instructions for use, whole blood capillary samples are collected from the puncture of the fingertip using high-flow lancets (not included with the HemoCue Hb 801 System), and filled directly into the microcuvette which is inserted into the HemoCue Hb Analyzer. The analyzer measures the whole blood at an Hb/HbO2 isosbestic point (506 nm) and at a wavelength (880 nm) to compensate for possible interfering background (e.g. turbidity). The measurement is performed directly on the whole blood through measurement of the transmitted and scattered light using an algorithm for translation into the hemoglobin concentration of the sample. The HemoCue Hb 801 System is traceable to the HiCN method, the international reference method according to International Council for Standardization in Hematology (ICSH) for the determination of the hemoglobin concentration in blood. The system is factory calibrated and needs no further calibration by the operator.

## M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Precision - Whole Blood

Venous K2EDTA whole blood samples were collected from six healthy subjects and processed to six hemoglobin (Hb) concentrations.

Multi-microcuvette lots

{5}

The six samples were analyzed at a single site over five days, with five runs, five replicates per run per day, and three microcuvette lots, providing 75 measurements for each Hb level. The HemoCue Hb 801 System demonstrates acceptable reproducibility across multiple lots of microcuvettes.

| Hb-levels (g/dL) | Replicates | Repeatability | | Within-Lab Precision | | Reproducibility | |
| --- | --- | --- | --- | --- | --- | --- | --- |
| | | SD (g/dL) | %CV | SD (g/dL) | %CV | SD (g/dL) | %CV |
| 2.0–3.0 | 75 | 0.05 | - | 0.05 | - | 0.05 | - |
| 6.0–7.0 | 75 | 0.07 | - | 0.08 | - | 0.08 | - |
| 9.5–10.5 | 75 | - | 0.68 | - | 0.71 | - | 1.11 |
| 13.5–14.5 | 75 | - | 0.71 | - | 0.82 | - | 1.16 |
| 16.5–17.0 | 75 | - | 0.60 | - | 0.73 | - | 0.95 |
| 23.0–24.0 | 75 | - | 0.67 | - | 0.77 | - | 0.97 |

# Multi-site study

Six venous $\mathrm{K}_2\mathrm{EDTA}$ whole blood samples were analyzed at three sites (one instrument per site) over five days, with five runs, five replicates per run, and one microcuvette lot, providing 75 measurements for each Hb level. The HemoCue Hb 801 System demonstrates acceptable reproducibility across multiple sites.

| Hb-levels (g/dL) | Replicates | Repeatability | | Within-Lab Precision | | Between-Site Precision | | Reproducibility | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | SD (g/dL) | %CV | SD (g/dL) | %CV | SD (g/dL) | %CV | SD (g/dL) | %CV |
| 2.0–3.0 | 75 | 0.03 | - | 0.04 | - | 0.01 | - | 0.05 | - |
| 6.0–7.0 | 75 | 0.07 | - | 0.07 | - | 0.03 | - | 0.08 | - |
| 9.5–10.5 | 75 | - | 1.04 | - | 1.17 | - | 1.13 | - | 1.63 |
| 13.5–14.5 | 75 | - | 0.71 | - | 0.75 | - | 0.66 | - | 1.00 |
| 16.5–17.0 | 75 | - | 0.52 | - | 0.63 | - | 0.21 | - | 0.66 |
| 23.0–24.0 | 75 | - | 0.74 | - | 0.74 | - | 0.49 | - | 0.89 |

# Precision - Quality Control Material

External hemoglobin control material (HemoTrol WB, manufactured by EuroTrol) at three different Hb-levels, was tested at three sites (one analyzer per site), three microcuvette lots (one lot per site), by ten operators (minimum 2 operators per site), over 20 operating days. The samples were tested with two runs per day and two replicates per run, providing 80 measurements for each level. The HemoCue Hb 801 System demonstrates acceptable reproducibility and between-operator precision.

| Control Level | N | Mean value (g/dL) | Repeatability | | Within-Site Precision | | Reproducibility | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | | | SD (g/dL) | %CV | SD (g/dL) | %CV | SD (g/dL) | %CV |
| Low | 240 | 6.34 | 0.05 | 0.70 | 0.04 | 0.70 | 0.06 | 0.90 |
| Medium | 240 | 11.50 | 0.05 | 0.40 | 0.05 | 0.50 | 0.06 | 0.50 |
| High | 240 | 15.36 | 0.15 | 1.00 | 0.16 | 1.00 | 0.17 | 1.10 |

{6}

7

| Control Level | Between-operator Precision | | | | | | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| | All Operators | | | | Operators in CLIA-waived setting | | | | POC Operators | | | |
| | N | Mean (g/dL) | SD (g/dL) | % CV | N | Mean (g/dL) | SD (g/dL) | % CV | N | Mean (g/dL) | SD (g/dL) | % CV |
| Low | 240 | 6.34 | 0.03 | - | 80 | 6.31 | 0.00 | - | 80 | 6.35 | 0.00 | - |
| Medium | 240 | 11.50 | - | 0.04 | 80 | 11.48 | - | 0.00 | 80 | 11.49 | - | 0.06 |
| High | 240 | 15.36 | - | 0.00 | 80 | 15.34 | - | 0.01 | 80 | 15.32 | - | 0.02 |

## Precision – K₂EDTA Whole Blood

Fourteen native venous K₂EDTA whole blood samples, Hb-level ranged 7.5–16.8 g/dL, were analyzed at one site over four days, with three instruments, one microcuvette lot, and ten replicates, providing 420 measurements. The HemoCue Hb 801 System demonstrates acceptable reproducibility with native venous K₂EDTA whole blood samples.

| Hb-Level group | Sample Number | Replicate Number | Repeatability %CV |
| --- | --- | --- | --- |
| Medical Decision level (MDL) (~7 g/dL) | 2 | 60 | 1.02 |
| Normal Hb-level (12–18 g/dL) | 12 | 360 | 0.97 |

## Precision-Capillary Blood

Forty-two capillary whole samples were analyzed at one site over four days, with one instrument, one microcuvette lot, and ten replicates, providing 420 measurements. The samples ranged 1.5–23.5 g/dL Hb concentration and included four K₂EDTA contrived samples to cover the MDL at 7 g/dL and the low and high ends of analytical measuring range (AMR). The HemoCue Hb 801 System demonstrates acceptable reproducibility with capillary blood samples.

| Hb-Level (g/dL) | Sample Number | Sample range (g/dL) | SD (g/dL) | %CV |
| --- | --- | --- | --- | --- |
| ≤7.0 | 2 | 1.4–5.0 | 0.11 | - |
| >7.0 | 40 | 7.1–23.3 | - | 2.30 |

## b. Linearity/assay reportable range:

One venous K₂EDTA blood sample was diluted to nine different Hb-levels (0.5, 3.78, 7.05, 10.33, 16.60, 16.88, 20.15, 23.43, and 26.7 g/dL) to span the claimed AMR of the HemoCue Hb 801 System (1.0–25.6 g/dL). Each Hb-level was analyzed with three analyzers and five replicates per analyzer. The HemoCue Hb 801 System demonstrates linearity over the claimed AMR of 1.0–25.6 g/dL.

## c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Microcuvette Shelf-Life

{7}

HemoCue Hb 801 Microcuvette shelf-life was determined by using three lots of microcuvettes with one lot kept open to study in-use stability over nine months (Time 0, 7 weeks, 3 months ± 2 weeks, 6 months ± 2 weeks, and 9 months). Measurements taken at these time points were compared with the hemiglobincyanide (HiCN) method. HiCN method is the ICSH reference method and was manually performed per ICSH recommendations. The absorbance was detected by a spectrometer. The data support a shelf-life stability claim of 6 months.

## Microcuvette Transportation

HemoCue Hb 801 Microcuvette stability during transportation was determined by using one lot of microcuvette over six months (Time 0, 2 weeks, 3 months ± 2 weeks, and 6 months ± 2 weeks). To mimic the transportation conditions, microcuvettes were cycled between two temperatures (-20±2°C and 52±2°C) and afterwards stored at one of the following storage temperatures, 5±3°C or 42±2°C. Measurements taken at these timepoints were compared with the HiCN method. The data support a transportation stability claim of 6 months.

## d. Detection limit:

### LoB

To determine Limit of Blank (LoB), plasma samples were obtained from four venous K₂EDTA whole blood samples. The study was conducted with three analyzers, two microcuvette lots, and over four operating days. Each sample was analyzed in three runs per day and two replicates per run, providing a total of 144 replicates. LoB was calculated by rank ordering the 72 samples per microcuvette lot from low to high and averaging the 68th and 69th results (being the 95th percentile). LoB was determined to be 0.26 g/dL.

### LoD

To determine Limit of Detection (LoD), four venous K₂EDTA whole blood samples were collected covering a Hb concentration range of 0.46–1.0 g/dL. The study was conducted with three analyzers, two microcuvette lots, and over four operating days. Each sample was analyzed three runs per day and two replicates per run, providing 72 replicates per microcuvette lot. LoD was calculated by nonparametric analysis and was determined to be 0.3 g/dL.

### LoQ

To determine Limit of Quantitation (LoQ), four venous K₂EDTA blood samples were collected covering Hb concentration 0.37–0.52 g/dL. The study was conducted with three analyzers, two microcuvette lots, and over four operating days. Each sample was analyzed three runs per day and three replicates per run, providing 108 replicates

8

{8}

per microcuvette lot. LoQ was determined from the specified total error to be 0.5 g/dL.

e. Analytical specificity:

Venous K₂EDTA whole blood samples were adjusted to two Hb levels (10.0±0.5 g/dL and 20.0±1.0 g/dL). The samples were divided into two groups: a test group and a reference group that serves as the control. The test group was spiked with the interfering substance in NaCl solution as the diluent solution; the reference group was added with a corresponding volume of diluent solution. Each condition (one hemoglobin level with one interfering substance or control) was analyzed with three blood samples, three analyzers, and five replicates per analyzer, providing a total of 45 replicates. A high concentration per CLSI EP07-A2 recommendation of each substance was tested. The results from the test groups were compared with the reference group and if the difference was within ±10%, no interference was determined to be the outcome. For substances identified as interferents at the high concentration tested, a concentration-response curve evaluating multiple concentrations of the interfering substance was generated to determine the non-interfering concentration.

To evaluate the impact on hemoglobin measurements by disease conditions, venous K₂EDTA blood specimens from 5–42 donors of each the following conditions were collected and tested: high white blood cell (WBC) count, sickle cell, polycythemia vera, thalassemia/hypochromia, microcytic hypochromic anemia, normocytic normochromic anemia, macrocytic anemia, autoimmune hemolytic anemia (spherocytosis), dual RBC populations (post-transfusion samples), NRBC, polychromasia, hemoglobin C disease, blood borne parasite (malaria), rouleaux, and agglutination. The Hb concentration from HemoCue Hb 801 System was compared to the HiCN method. Each sample was tested in three or five replicates on HemoCue Hb 801 System and 2–3 replicates with HiCN method. The following conditions, within the acceptance criteria demonstrated no interference effect on the HemoCue Hb 801 System: sickle cell, polycythemia vera, thalassemia/hypochromia, microcytic hypochromic anemia, normocytic normochromic anemia, macrocytic anemia, autoimmune hemolytic anemia (spherocytosis), dual RBC populations (post-transfusion samples), NRBC, polychromasia, hemoglobin C disease, blood borne parasite (malaria), rouleaux, and agglutination.

Substances showed no significant interference up to the concentrations listed below:

| Potential interferent | Test concentration | Unit | Potential interferent | Test concentration | Unit |
| --- | --- | --- | --- | --- | --- |
| Acetaminophen | 1324 | μmol/L | Intralipid | 214 | mg/dL |
| Creatinine | 442 | μmol/L | Conjugated bilirubin | 23 | mg/dL |
| Ibuprofen | 2425 | μmol/L | Unconjugated bilirubin | 12 | mg/dL |
| Simvastatin | 49 | μmol/L | Hemolysis | 1 | g/dL |

{9}

| Potential interferent | Test concentration | Unit | Potential interferent | Test concentration | Unit |
| --- | --- | --- | --- | --- | --- |
| Tetracycline | 34 | μmol/L | HbCO | 10 | % |
| Warfarin | 32.5 | μmol/L | HbO2 Low | 50 | % |
| Ascorbic acid | 342 | μmol/L | MetHb | 25 | % |
| Salicylic acid | 4.34 | mmol/L | pH | 8 | N/A |
| Urea | 42.9 | mmol/L | Li-Heparin | 5 × normal concentration (85 IU/mL blood) | |
| Uric acid | 1.4 | mmol/L | K_{2}EDTA | 5 × normal concentration (9 mg/mL blood) | |
| Protein | 15 | mg/dL | Platelets | 2000 × 10^{9} | cells/L |
| Triglycerides | 1500 | mg/dL | WBC | 260 × 10^{9} | cells/L |

The following substances were found to interfere at the indicated concentrations:

| Substance | Substance Concentration | Hemoglobin Concentration Tested | Results |
| --- | --- | --- | --- |
| Conjugated bilirubin | > 23 mg/dL | 10 | Interfering |
| | ≤ 40 mg/dL | 20 | Non-interfering |
| Unconjugated bilirubin | > 12 mg/dL | 10 | Interfering |
| | > 23 mg/dL | 20 | Interfering |
| Intralipid | > 214 mg/dL | 10 | Interfering |
| | > 483 mg/dL | 20 | Interfering |
| Leukocytes | > 260 × 10^{9}/L | 6.8–14.7 | Interfering |

f. Assay cut-off:

Not applicable

2. Comparison studies:

a. Method comparison with predicate device:

Method comparison studies were performed across five point-of-care (POC) sites to compare the HemoCue Hb 801 System to the predicate device, the HemoCue Hb 301 System. A total of 233 capillary samples and 264 venous K₂EDTA whole blood specimens from a total of 285 subjects were tested at five U.S. sites of primary care setting with both the Hemocue Hb 801 System and the predicate. All samples were measured in duplicate and only the first replicate for each sample was used for the data analysis.

A total of 135 male and 150 female subjects, ranging from 29 days to 95 years of age, provided 233 capillary samples ranging from 4.7–23.2 g/dL and 264 venous K₂EDTA samples ranging from 1.5–25.3 g/dL when tested on the HemoCue Hb 801 System. Of the 497 samples, 28 (6%) contrived venous K₂EDTA samples were collected at one site and tested to challenge the full measuring range of the HemoCue Hb 801 System. In addition, the samples tested for the method comparison study included

{10}

samples from patients with anemia and thalassemia as well as samples around the lower medical decision levels.

Testing was performed by 13 operators (2-3 per site) using six analyzers (1-2 per site) and three lots of HemoCue Hb 801 microcuvettes. Linear regression analyses demonstrate comparable performance between the HemoCue Hb 801 System across the AMR.

| Blood Type | Sample Number | Slope (95% CI) | Intercept (95% CI) | r |
| --- | --- | --- | --- | --- |
| Venous | 264 | 1.00 (0.99, 1.01) | -0.14 (-0.26, -0.33) | 1.00 |
| Capillary | 233 | 1.07 (1.02 to 1.12) | -0.91 (-1.54 to -0.28) | 0.96 |
| Combined | 497 | 1.01 (1.00, 1.02) | -0.19 (-0.33, -0.06) | 0.99 |

Predicted bias at MDL $7\mathrm{g / dL}$ along with $95\%$ CIs:

| Blood Type | Mean Bias at MDL 7 g/dL (95% CI) (g/dL) |
| --- | --- |
| Venous | -0.1 (-0.2, -0.1) |
| Capillary | -0.4 (-0.7, -0.1) |
| Combined | -0.1 (-0.2, -0.1) |

# b. Matrix comparison:

A comparison between $\mathrm{K}_2\mathrm{EDTA}$ and Li-heparin venous blood was performed on HemoCue Hb 801 System. Paired natural $\mathrm{K}_2\mathrm{EDTA}$ and Li-heparin samples (n=131), ranging from 2.4-23.6 ( $\mathrm{K}_2\mathrm{EDTA}$ ) or 2.5-23.4 (Li-heparin) g/dL Hb, demonstrated comparable performance. In addition, a comparison between capillary and venous $\mathrm{K}_2\mathrm{EDTA}$ blood was performed on the HemoCue Hb 801 System. Paired capillary and venous $\mathrm{K}_2\mathrm{EDTA}$ samples without anticoagulant (n=212), ranging from 4.7-23.2 (capillary) or 4.8-23.4 ( $\mathrm{K}_2\mathrm{EDTA}$ ) g/dL Hb, demonstrated comparable performance.

| Comparison | Sample Number | Slope (95% CI) | Intercept (95% CI) | r |
| --- | --- | --- | --- | --- |
| K2EDTA vs Li-Heparin venous whole blood | 131 | 0.99 (0.99, 1.00) | 0.12 (0.06, 0.17) | 1.00 |
| Venous vs Capillary | 252 | 1.01 (0.98, 1.03) | -0.05 (-0.33, 0.23) | 0.95 |

Predicted bias at MDL $7\mathrm{g / dL}$ along with $95\%$ CIs:

| Comparison | Mean Bias at MDL 7 g/dL (95% CI) |
| --- | --- |
| K2EDTA vs Li-Heparin venous whole blood | -0.2% (-2.3%, 1.9%) |
| Venous vs Capillary | 1.1% (0.6%, 1.5%) |

# 3. Clinical studies:

{11}

a. Clinical Sensitivity:

Not applicable

b. Clinical specificity:

Not applicable

c. Other clinical supportive data (when a. and b. are not applicable):

Not applicable

4. Clinical cut-off:

Not applicable

5. Expected values/Reference range:

Reference ranges were verified by testing whole blood specimens from healthy donors using the HemoCue Hb 801 System. The reference ranges were based on the existing medically accepted published reference ranges $^{1,2}$ .

| Population | Age Range | Sample Number Tested | Cited Reference Range (g/dL) |
| --- | --- | --- | --- |
| Adult Male | ≥ 22 years | 45 | 13.0–17.01 |
| Adult Female | ≥ 22 years | 43 | 12.0–15.01 |
| Adolescent | 12 years to < 18 years old | 20 | 10.9–15.12 |
| Child | > 2 years to 12 years | 24 | 11.0–15.51 |
| Infant | 1 month to 2 years | 28 | 9.4–14.11 |

1 Dacie and Lewis Practical Haematology, Elsevier Limited, 11th Edition, 2011 and references herein
2 Soldin, S. J. Pediatric Reference Intervals, AACC Press; 7th edition, 2011

N. Instrument Name:

HemoCue Hb 801 System

O. System Descriptions:

1. Modes of Operation:

Does the applicant's device contain the ability to transmit data to a computer, webserver, or mobile device?

Yes ☐ X ☐ or No ☐

{12}

Does the applicant’s device transmit data to a computer, webserver, or mobile device using wireless transmission?

Yes ☐ X ☐ or No ☐

2. Software:

FDA has reviewed applicant’s Hazard Analysis and software development processes for this line of product types:

Yes ☐ X ☐ or No ☐

3. Specimen Identification:

There is no sample identification function for the HemoCue Hb 801 system.

4. Specimen Sampling and Handling:

The Hemocue 801 microcuvette draws a small amount (approximately 10μL) of venous or capillary blood by capillary effect. The cuvette is then inserted into the meter. No reagent is required.

5. Calibration:

The HemoCue Hb 801 Analyzer is factory calibrated and needs no further calibration.

6. Quality Control:

The HemoCue Hb 801 System is intended to be used with the HemoTrol WB control materials, manufactured by EuroTrol, in three concentrations that correspond to three levels of human hemoglobin (~95, 130, and 160 g/L). Each vial contains 1 mL of HemoTrol WB solution that contains purified bovine hemolysate, stabilizer, and preservatives. Users are directed to perform control testing when an external quality control is required by local or other regulations. The EuroTrol HemoTrol WB is concurrently cleared under K182744.

P. Other Supportive Instrument Performance Characteristics Data Not Covered In The "Performance Characteristics" Section above:

a. Operating Environment

The operation of HemoCue Hb 801 was tested under the following three conditions: 8–10°C and ≤30% relative humidity (RH); 24–26°C and ≥90% RH; 40–42°C and 75–80% RH. Three contrived venous K₂EDTA samples at hemoglobin levels 5.0±0.5, 14.0±0.5, and 20.0±1.0 g/dL were tested over three operating days. Acceptable results were achieved under all conditions tested.

13

{13}

b. Cleaning and Disinfection Validation Study

A cleaning and disinfection validation study was conducted to validate virucidal efficacy using the selected disinfectant with the recommended disinfection protocol. Super Sani-Cloth Germicidal Disposable Wipes (EPA Registration No. 9480-4), a ready to use pre-saturated towelette, demonstrated complete inactivation of Duck Hepatitis B virus (surrogate for Human Hepatitis B virus) for all tested materials, following 2-minute wet-contact time. Results of the study also demonstrate no significant change in appearance and function of the HemoCue Hb 801 System after 3000 disinfection and cleaning cycles.

c. Accuracy

An accuracy study was performed by testing 102 venous K₂EDTA whole blood samples (45% contrived) and 100 capillary blood samples on the HemoCue Hb 801 System and using HiCN method. Samples were tested on one analyzer Hemocue Hb 801 System, three lots of microcuvette, over ten days. The regression analysis of venous or capillary samples suggested an agreement between HemoCue Hb 801 System and HiCN method (ICSH reference method).

| Blood Type | Sample Number | Slope | Intercept | r |
| --- | --- | --- | --- | --- |
| Venous | 102 | 0.99 | 0.087 | 1.00 |
| Capillary | 100 | 0.96 | 0.92 | 0.92 |

d. Sample Stability

Sample stability was assessed using five venous K₂EDTA whole blood samples at either room temperature (23±2°C) or refrigerated temperature (5±3°C). All samples were analyzed with one lot of microcuvette, three analyzers, and four replicates over 25 hours (0, 4, 8, 20, and 25 hours). The study data supported the recommended stability claim of 24 hours when stored at room temperature (23±2°C) or refrigerated temperature (5±3°C).

Q. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

R. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.